Medtelligence: Linking Science to Clinical Practice - Medtelligence

Medtelligence Hero

Linking Science
to Clinical Practice

Innovative, high-quality medical education for clinicians in cardiology and other specialties.

Featured

Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CE
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
0.25 credits
- Richard Lafayette, MD, FACP
- Ankana Daga, MD
0.25 credits
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
MinuteCE®
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
1.00 credit 6 episodes
- Ahmad Masri, MD, MS
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 credit 6 episodes
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CE
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
0.25 credits
- An De Vriese, MD, PhD
- Muh Geot Wong, MBBS, PhD
0.25 credits

Popular

Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
- Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
- Joseph Rossano, MD
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CE
Inside the IgAN Clinic: Shared Decision-Making Into Practice
0.25 credits
- Jonathan Barratt, MD, PhD
0.25 credits
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
CME/CE In-Person Event
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
1.00 credit
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
CME/CE In-Person Event
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
June 04, 2026
Glasgow
1.00 credit
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME/CE
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
0.25 credits
- Steven Fishbane, MD
- Maurizio Gallieni, MD
0.25 credits